0001735276-18-000048.txt : 20180814
0001735276-18-000048.hdr.sgml : 20180814
20180814175410
ACCESSION NUMBER: 0001735276-18-000048
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180813
FILED AS OF DATE: 20180814
DATE AS OF CHANGE: 20180814
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Soni Manmeet Singh
CENTRAL INDEX KEY: 0001569769
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36407
FILM NUMBER: 181019177
MAIL ADDRESS:
STREET 1: C/O PHARMACYCLICS, INC.
STREET 2: 995 EAST ARQUES AVE
CITY: SUNNYVALE
STATE: CA
ZIP: 94085
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALNYLAM PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001178670
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770602661
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 THIRD STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 551-8200
MAIL ADDRESS:
STREET 1: 300 THIRD STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: ALNYLAM PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20020724
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2018-08-13
0
0001178670
ALNYLAM PHARMACEUTICALS, INC.
ALNY
0001569769
Soni Manmeet Singh
300 THIRD STREET
CAMBRIDGE
MA
02142
0
1
0
0
Chief Financial Officer
Common Stock
2017-07-25
5
J
0
2
0.0
A
2
I
by Managed Account
Common Stock
2017-10-16
5
J
0
11
0.0
A
13
I
by Managed Account
Common Stock
2018-01-17
5
J
0
6
0.0
A
19
I
by Managed Account
Common Stock
2018-04-16
5
J
0
28
0.0
A
47
I
by Managed Account
Common Stock
2018-07-10
5
J
0
36
0.0
A
83
I
by Managed Account
Performance Stock Option 2017 (right to buy)
52.61
2018-08-13
4
A
0
25000
0.0
A
2018-08-13
2027-05-08
Common Stock
25000
25000
D
Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
On May 8, 2017, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. The shares subject to the option will vest upon the commercial launch of Alnylams first internally developed product, as approved by our compensation committee. Effective August 13, 2018, the compensation committee of the Company determined the performance criterion has been met and the option shares have vested.
By: /s/ Michael P. Mason, Attorney-in-Fact For: Manmeet S Soni
2018-08-14